Cargando…
A novel small molecule inhibitor of p32 mitochondrial protein overexpressed in glioma
BACKGROUND: The mitochondrial protein p32 is a validated therapeutic target of cancer overexpressed in glioma. Therapeutic targeting of p32 with monoclonal antibody or p32-binding LyP-1 tumor-homing peptide can limit tumor growth. However, these agents do not specifically target mitochondrial-locali...
Autores principales: | Yenugonda, Venkata, Nomura, Natsuko, Kouznetsova, Valentina, Tsigelny, Igor, Fogal, Valentina, Nurmemmedov, Elmar, Kesari, Santosh, Babic, Ivan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648515/ https://www.ncbi.nlm.nih.gov/pubmed/29047383 http://dx.doi.org/10.1186/s12967-017-1312-7 |
Ejemplares similares
-
Allosteric inhibitor of β-catenin selectively targets oncogenic Wnt signaling in colon cancer
por: Cheltsov, Anton, et al.
Publicado: (2020) -
Multiple spatially related pharmacophores define small molecule inhibitors of OLIG2 in glioblastoma
por: Tsigelny, Igor F., et al.
Publicado: (2015) -
Molecular mechanisms of OLIG2 transcription factor in brain cancer
por: Tsigelny, Igor F., et al.
Publicado: (2016) -
The role of BAG3 in dilated cardiomyopathy and its association with Charcot-Marie-Tooth disease type 2
por: Yerabandi, Nitya, et al.
Publicado: (2022) -
Two-Stage Deep-Learning Classifier for Diagnostics of Lung Cancer Using Metabolites
por: Choudhary, Ashvin, et al.
Publicado: (2023)